Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
C4 Therapeutics, Inc. - Common Stock
(NQ:
CCCC
)
5.890
-0.340 (-5.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about C4 Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
September 13, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
September 10, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
September 08, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
September 03, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Inc. (NASDAQ: CCCC) Leading the Way in Wednesday Trading Based on Percentage Gain
January 10, 2024
Via
Investor Brand Network
C4 Therapeutics to Participate in Upcoming September Investor Conferences
August 29, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation
August 14, 2024
Investor Webcast Moved to Friday, September 13, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 01, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
July 16, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
July 08, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
June 10, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 08, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 29, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
April 09, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
April 08, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
March 05, 2024
CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
March 04, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
February 22, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
January 09, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals
January 04, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
MarketBeat Week in Review – 12/18 - 12/22
December 23, 2023
The torrid stock market rally cooled down a little bit heading into the extended holiday weekend; we wish you a Happy Holiday season with friends and family
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
C4 Therapeutics blasts off: what's next?
December 18, 2023
As the market soars to new heights, C4 Therapeutics (NASDAQ: CCCC) has become the latest small-cap stock to explode higher in price and volume.
Via
MarketBeat
Topics
ETFs
C4 Therapeutics Inc. (NASDAQ: CCCC) Near Top of Volume Charts in Friday Trading
December 15, 2023
Via
Investor Brand Network
C4 Therapeutics Inc. (NASDAQ: CCCC) is One of Thursday Morning’s Most Active Stocks
December 14, 2023
Via
Investor Brand Network
C4 Therapeutics Inc. (NASDAQ: CCCC) is One of Wednesday Morning’s Most Active Stocks
December 13, 2023
Via
Investor Brand Network
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma
December 12, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)
December 12, 2023
Initial Focus on One Oncology Target, Exclusive to Collaboration; Merck has Option for Three Additional Targets
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma
November 28, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
November 20, 2023
Owen Hughes, Accomplished Life Sciences Executive with Deep Experience Across Investing, Operations and Governance, Appointed as Independent Member of the Board of Directors
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.